GENFLEET-B(02595): Multiple innovative combination therapies of the oral pan-RAS inhibitor GFH276 have recently received clinical trial approval, with clinical studies being conducted in China or overseas for first-line and later-line treatment of major-indication tumor types.

GenFleet Therapeutics-B (02595) announced that since the third quarter of this year, multiple innovative combination therapies of the oral pan-RAS inhibitor GFH276 have received clinical trial approval from China's CDE or completed clinical trial filing with Australia's TGA. The related studies cover first-line and later-line treatment of multiple major-indication tumor types with RAS mutations, and some trials have already enrolled patients at multiple dose levels.